FDA develops resources about biosimilars for HCPs; Biogen negotiates royalties for experimental Alzheimer’s drug; GSK Q3 sales driven by HIV, respiratory drugs
Five things for pharma marketers to know: Friday, April 21, 2017
Teva launches branded competitor to GSK’s Advair; Valeant prices psoriasis drug at $3,500 per month; overseas drug importation would save money, op-ed argues
David Van Sickle, Propeller Health
April 4, 2017
11:00 am
David Van Sickle is CEO and co-founder of Propeller Health.
Drugmakers target severe asthma patients with biologics, but payers raise pricing issue